Literature DB >> 27809519

Highly Promiscuous Small Molecules from Biological Screening Assays Include Many Pan-Assay Interference Compounds but Also Candidates for Polypharmacology.

Erik Gilberg1, Swarit Jasial1, Dagmar Stumpfe1, Dilyana Dimova1, Jürgen Bajorath1.   

Abstract

In PubChem screening assays, 466 highly promiscuous compounds were identified that were examined for known pan-assay interference compounds (PAINS) and aggregators using publicly available filters. These filters detected 210 PAINS and 67 aggregators. Compounds passing the filters included additional PAINS that were not detected, mostly due to tautomerism, and a variety of other potentially reactive compounds currently not encoded as PAINS. For a subset of compounds passing the filters, there was no evidence of potential artifacts. These compounds are considered candidates for further exploring multitarget activities and the molecular basis of polypharmacology.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27809519     DOI: 10.1021/acs.jmedchem.6b01314

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  10 in total

1.  Enhancing Molecular Promiscuity Evaluation Through Assay Profiles.

Authors:  Sorin Avram; Ramona Curpan; Alina Bora; Cristian Neanu; Liliana Halip
Journal:  Pharm Res       Date:  2018-10-18       Impact factor: 4.200

Review 2.  Polypharmacology of conformationally locked methanocarba nucleosides.

Authors:  Kenneth A Jacobson; Dilip K Tosh; Kiran S Toti; Antonella Ciancetta
Journal:  Drug Discov Today       Date:  2017-08-03       Impact factor: 7.851

3.  Identification of Inhibitors of the dNTP Triphosphohydrolase SAMHD1 Using a Novel and Direct High-Throughput Assay.

Authors:  Christopher H Mauney; Fred W Perrino; Thomas Hollis
Journal:  Biochemistry       Date:  2018-11-13       Impact factor: 3.162

4.  Towards a systematic assessment of assay interference: Identification of extensively tested compounds with high assay promiscuity.

Authors:  Erik Gilberg; Dagmar Stumpfe; Jürgen Bajorath
Journal:  F1000Res       Date:  2017-08-17

5.  Chemistry-based molecular signature underlying the atypia of clozapine.

Authors:  T Cardozo; E Shmelkov; K Felsovalyi; J Swetnam; T Butler; D Malaspina; S V Shmelkov
Journal:  Transl Psychiatry       Date:  2017-02-21       Impact factor: 6.222

Review 6.  Benchmarking Data Sets from PubChem BioAssay Data: Current Scenario and Room for Improvement.

Authors:  Viet-Khoa Tran-Nguyen; Didier Rognan
Journal:  Int J Mol Sci       Date:  2020-06-19       Impact factor: 5.923

7.  X-ray-Structure-Based Identification of Compounds with Activity against Targets from Different Families and Generation of Templates for Multitarget Ligand Design.

Authors:  Erik Gilberg; Dagmar Stumpfe; Jürgen Bajorath
Journal:  ACS Omega       Date:  2018-01-05

Review 8.  Gains from no real PAINS: Where 'Fair Trial Strategy' stands in the development of multi-target ligands.

Authors:  Jianbo Sun; Hui Zhong; Kun Wang; Na Li; Li Chen
Journal:  Acta Pharm Sin B       Date:  2021-03-04       Impact factor: 11.413

Review 9.  The diverse mechanisms and anticancer potential of naphthoquinones.

Authors:  Carolina Escardó Pereyra; Rafael Ferreira Dantas; Sabrina Baptista Ferreira; Luciano Pinho Gomes; Floriano Paes Silva-Jr
Journal:  Cancer Cell Int       Date:  2019-08-02       Impact factor: 5.722

Review 10.  The Transporter-Mediated Cellular Uptake and Efflux of Pharmaceutical Drugs and Biotechnology Products: How and Why Phospholipid Bilayer Transport Is Negligible in Real Biomembranes.

Authors:  Douglas B Kell
Journal:  Molecules       Date:  2021-09-16       Impact factor: 4.411

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.